Search clinical trials for: nivolumab, ipilimumab

Total 1954 results

National Cancer Institute (NCI)

Withdrawn

Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

Merkel Cell Carcinoma
Bristol-Myers Squibb

Active, not recruiting

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Melanoma

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Not yet recruiting

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals

Not yet recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Melanoma
Antengene Therapeutics Limited
Bristol-Myers Squibb

Recruiting

Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies (ERASER)

Solid Tumor | Hematological Malignancy

Australia
John Kirkwood
Bristol-Myers Squibb

Active, not recruiting

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Melanoma

United States
Mayo Clinic

Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Malignant Solid Neoplasm | Renal Cell Carcinoma | Hepatocellular Carcinoma | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditions

United States
ImmunSYS, LLC

Recruiting

Metastatic Solid Cancer Clinical Trial

Metastatic Cancer

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Second Affiliated Hospital, School of Medicine,...

Completed

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

High-Risk Resectable NSCLC

China
University of Louisville
James Graham Brown Cancer Center

Terminated

Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Sarcoma | Lymphoma | Neuroblastoma | Wilm's Tumor

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma (ILP+/-IPI)

In-transit Metastases Melanoma Stage IIIB and IIIC

France
Bristol-Myers Squibb

Completed

YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Advanced Melanoma

United States, United Kingdom
University College, London
Bristol-Myers Squibb

Terminated

A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma (NeAT Glio)

Glioblastoma

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

Epilepsy

United States, France, Poland, Taiwan, Argentina, South Africa, Belgium, Germany, Russian Federation, Austria, Hungary, Canada, Philippines, Australia
Duke University

Completed

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Unresectable Melanoma

United States
Universitair Ziekenhuis Brussel

Recruiting

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors (Luscid)

Solid Tumor | Non Small Cell Lung Cancer

Belgium
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
Jason J. Luke, MD
Bristol-Myers Squibb

Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Unresectable Solid Tumors

United States
Eric Bernicker, MD

Terminated

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma (ENSIGN)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Metastatic Uveal Melanoma | Lung Squamous Cell Carcinoma Stage IV

United States
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
University of Colorado, Denver
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Malignant Melanoma

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)

Breast Cancer

China, Russian Federation, United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Ireland, Korea, Republic of, Mexico, Netherlands, Poland, Portuga... and more
Amsterdam UMC, location VUmc
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Active, not recruiting

Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

Myeloma

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Withdrawn

SBRT as a Vaccination for Metastatic Melanoma

Metastatic Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Bristol-Myers Squibb

Completed

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Small Cell Lung Carcinoma

Germany, Korea, Republic of, Poland, Taiwan, United States, China, Hong Kong, Spain, Australia, Italy, Russian Federation, Mexico, France, Japan, Switzerland, Austria, Belgium, Canada, Czechia, Hungary, Ireland, Israel, Netherlands, Peru and more
Alden Cancer Therapy II
Haukeland University Hospital; Norwegian Radium Hospital

Completed

Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (CryoIT)

Prostate Cancer

Norway
Bristol-Myers Squibb

Terminated

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)

Urinary Bladder Neoplasms

United States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
Fundación GECP

Recruiting

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)

Lung Cancer | Non Small Cell Lung Cancer | Brain Metastases, Adult

Spain
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditions

United States
Bristol-Myers Squibb

Completed

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (CheckMate 568)

Non-Small-Cell Lung Cancer

United States, Canada
Inge Marie Svane

Unknown

Adoptive Cell Therapy Across Cancer Diagnoses

Cancer

Denmark
RAPT Therapeutics, Inc.

Terminated

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Advanced Melanoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Healthy Subjects

China
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Mel-Ipi-Rx)

Malignant Melanoma

France
Memorial Sloan Kettering Cancer Center

Completed

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Breast Cancer | Invasive Adenocarcinoma of the Breast

United States
Bristol-Myers Squibb
JSS Medical Research Inc.

Completed

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Melanoma

Venezuela
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

United States, United Kingdom
Anaveon AG

Recruiting

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer. (ANV419-001)

Lung Cancer | Advanced Solid Tumor | Adult Disease

United Kingdom, Switzerland, Spain
Grupo Español Multidisciplinar de Melanoma
Bristol-Myers Squibb

Completed

GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (GRAY-B)

Melanoma | Brain Metastases

Spain
Threshold Pharmaceuticals
M.D. Anderson Cancer Center

Unknown

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Melanoma | Pancreatic Cancer | Prostate Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Prof. Dr. med. Dirk Schadendorf

Completed

THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (DeCOG)

Ocular Melanoma

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Phase 1 Bioavailability Study of Topiramate Oral Liquid Formulation Compared to the Marketed Sprinkle Capsule Formulation in Healthy Adults

Epilepsy
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)

Non Small Cell Lung Cancer

United States, China, Hungary, Brazil, Argentina, Canada, France, Greece, Italy, Japan, Korea, Republic of, Romania, Spain, Taiwan, Turkey
Inge Marie Svane

Completed

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Metastatic Ovarian Cancer

Denmark
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland

Search clinical trials for: nivolumab, ipilimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations